Alcoholic hepatitis (AH) is an acute inflammatory liver condition with high early mortality rate. Steroids improve shortterm survival but nonresponders have the worst outcomes. There is a clinical need to identify these high-risk individuals at the time of presentation. T cells are implicated in AH and steroid responsiveness. We measured ex vivo T cell cytokine expression as a candidate biomarker of outcomes in patients with AH. Consecutive patients (bilirubin >80 µmol/L and ratio of aspartate aminotransferase to alanine aminotransferase >1.5 who were heavy alcohol consumers with discriminant function [DF] ≥32), were recruited from University Hospitals Plymouth NHS Trust. T cells were obtained and stimulated ex vivo. Cytokine expression levels were determined by flow cytometry and protein multiplex analysis. Twenty-three patients were recruited (10 male; median age 51 years; baseline DF 67; 30% 90-day mortality). Compared to T cells from nonsurvivors at day 90, T cells from survivors had higher baseline baseline intracellular interleukin (IL)-10:IL-17A ratio (0.43 vs 1.20, p=0.02). Multiplex protein analysis identified interferon γ (IFNγ) and tumor necrosis factor-α (TNF-α) as independent predictors of 90-day mortality (p=0.04, p=0.01, respectively). The ratio of IFNγ to TNF-α was predictive of 90-day mortality (1.4 vs 0.2, p=0.03). These data demonstrate the potential utility of T cell cytokine release assays performed on pretreatment blood samples as biomarkers of survival in patients with severe AH. Our key findings were that intracellular IL-10:IL-17A and IFNγ:TNF-α in culture supernatants were predictors of 90-day mortality. This offers the promise of developing T cell-based diagnostic tools for risk stratification. (Gut Liver 2020;14:265-268) 
INTRODUCTION
Alcoholic hepatitis (AH) is an acute inflammatory condition, which carries a high mortality of 30% within 90 days. 1 Steroid treatment is the only therapy with proven short-term survival benefit. 2 However, the worst outcomes are in the 30% to 40% of patients with a poor response to steroid treatment, 3 and there is a pressing need to identify these high-risk individuals at presentation. T cells have long been implicated in the pathogenesis of AH and we have previously reported that suppression of lymphocyte proliferation correlates with clinical outcome following steroid treatment. 4, 5 Given the barriers to the development of this radiation-based assay for clinical application and the precedent of functional cytokine release assays for other clinical applications, 6 we sought to evaluate T cell cytokine expression as a candidate biomarker of AH mortality.
CASE REPORT 1. Study design
The study protocol was approved by the UK's Health Research Authority (reference: 15/LO/1501) and all participants provided written informed consent. Consecutive patients with severe AH, defined as recent onset jaundice with bilirubin >80 µmol/L and ratio of aspartate aminotransferase to alanine aminotransferase >1.5 in heavy alcohol consumers (>60 g or 80 g ethanol/day in females and males respectively) with a discriminant function (DF) score ≥32, were recruited from University Hospitals Plymouth NHS Trust. Patients received standard care including steroid treatment in the absence of active infection, hepatorenal syndrome or gastrointestinal hemorrhage. Multiplex protein analysis performed on 22 of the 23 cases identified IFNγ and TNF-α as most differentially expressed between survivors and nonsurvivors at day 90 (7,044 pg/mL vs 2,741 pg/mL, p=0.19 and 2,610 pg/mL vs 4,098 pg/mL, p=0.08, respectively). Multivariate analysis confirmed that both IFNγ and TNF-α were independent predictors of 90-day mortality (p=0.04 and p=0.01, respectively). The ratio of IFNγ to TNF-α was predictive of 90-day mortality (1.4 vs 0.2, p=0.03) (Fig. 1B) with an area under the curve of the receiver operating characteristic score of 0.79 (95% confidence interval, 0.58 to 0.99).
T cell isolation, stimulation and statistical analysis
The concentration of other mediators tested in the multiplex was similar between survivors and nonsurvivors. No cytokine concentration correlated with baseline DF or MELD scores. Steroid response, as determined by Lille score with a threshold of 0.45 at day 7 of steroid treatment, was not associated with differences in any cytokine measured by either flow cytometry or protein multiplex. Similarly, the ratios of intracellular IL-10/IL-17A and IFNγ/TNF-α were the same in Lille steroid responders and nonresponders. 
DISCUSSION
These data from a pilot prospective cohort of more than 20 patients demonstrate the potential utility of T cell cytokine release assays performed on pretreatment blood samples as biomarkers of survival in severe AH. Our key findings were that both the ratio of intracellular IL-10 to IL-17A measured by flow cytometry in CD4 + cells and the ratio of IFNγ to TNF-α in culture supernatants were predictors of 90-day mortality. These data also demonstrate that flow cytometry and protein multiplex are complementary techniques that can reveal different alterations in protein expression either in proportion of cells secreting a cytokine or in cytokine concentration, respectively. The pathogenesis of AH is orchestrated by several immune subsets including neutrophils and monocytes, which are activated by gut derived signals such as endotoxin. 8, 9 However, T cells also play a vital role in responding to antigen presenting cells and propagating inflammation in AH. 10 Transcriptome studies have confirmed upregulation of TNF and T cell pathways. 11, 12 In particular, the Th17 (IL-17 expressing T cell) pathway is upregulated with high expression of related chemokines such as CCL20. 12, 13 Furthermore, recent studies have demonstrated that monocytes activated by exposure to gut microbial signals interact with CD4 + T cells to alter expression of exhaustion markers and cytokines including IFNγ. 14 These data confirm the relevance of T cells in AH and support the measurement of T cell cytokines as a broad measure of immune response. These findings offer the promise of developing T cell based diagnostic tools for risk stratification both in the context of routine clinical practice and also to inform the design of smart clinical trials seeking to test new interventions in patients most likely to fail conventional corticosteroid therapy. L.P.S. and R.W.J.L are named inventors on a US patent application (number: 61/919,404), which incorporates biomarkers to identify patients who will benefit from treatments for inflammatory diseases.
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